Comparative Pharmacology
Head-to-head clinical analysis: CHLORPHENIRAMINE MALEATE versus PYRILAMINE MALEATE.
Head-to-head clinical analysis: CHLORPHENIRAMINE MALEATE versus PYRILAMINE MALEATE.
CHLORPHENIRAMINE MALEATE vs PYRILAMINE MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
H1 receptor antagonist; competitively blocks histamine at H1 receptors, preventing histamine-mediated symptoms such as vasodilation, increased capillary permeability, and smooth muscle contraction.
Pyrilamine is a first-generation antihistamine that competitively antagonizes histamine at H1 receptors, thereby preventing histamine-mediated effects such as increased vascular permeability, vasodilation, and bronchoconstriction.
4 mg orally every 4-6 hours, not to exceed 24 mg per day; or 10-20 mg intramuscularly or intravenously as a single dose, not to exceed 40 mg per day.
25-50 mg orally every 6-8 hours as needed, not to exceed 200 mg per day.
None Documented
None Documented
Clinical Note
moderateDexchlorpheniramine maleate + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Dexchlorpheniramine maleate."
Clinical Note
moderateDexchlorpheniramine maleate + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Dexchlorpheniramine maleate."
Clinical Note
moderateDexchlorpheniramine maleate + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Dexchlorpheniramine maleate."
Clinical Note
moderateTerminal elimination half-life: 12-15 hours (prolonged in hepatic impairment).
Approximately 16-23 hours in healthy adults; may be prolonged in elderly or hepatic impairment.
Renal: ~50% as metabolites; Fecal: negligible; Biliary: minor.
Primarily renal as metabolites; about 80-90% excreted in urine within 24 hours, with less than 5% unchanged; minor biliary/fecal elimination.
Category C
Category C
Antihistamine
Antihistamine
Dexchlorpheniramine maleate + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Dexchlorpheniramine maleate."